Guanzhong Zhang,Zhaozhe Liu,Tao Han,Fang Guo,Qingqing Sun,Yanan Ge,Yaling Han,Xiaodong Xie. Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer. Oncol Transl Med, 2014, 13: 528-531.
Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer
Received:September 11, 2014  Revised:November 03, 2014
View Full Text  View/Add Comment  Download reader
KeyWord:small cell lung cancer (SCLC); etoposide capsule; cisplatin; carboplatin; elderly
Author NameAffiliationE-mail
Guanzhong Zhang Oncology Department, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China 110016 gzzhang2009@126.com 
Zhaozhe Liu Oncology Department, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China 110016 lzz_summer@126.com 
Tao Han Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning  
Fang Guo Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning  
Qingqing Sun Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning  
Yanan Ge Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning  
Yaling Han Cardiovascular disease institute,General Hospital of Shenyang Military Region,Shenyang,Liaoning  
Xiaodong Xie Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning doctor_xxd@163.com 
Hits: 8483
Download times: 8374
Abstract:
      Objective: We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71–79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150–175 mg, d1–5, combined with cisplatin 20 mg/m2 d1–3 or carboplatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results: After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), and 3 cases had progression of disease (PD). The objective response rate was 65.6% (21/32), disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of I/II leukopenia and astrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.
Close